Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chemokine Modulation and Pembrolizumab in Metastatic TNBC
NCT03599453Phase 1Completed
- Sponsor
- Roswell Park Comprehensive Cancer Center
- Start
- Jan 2019
- Primary completion
- Sep 2020
- Modality
- Antisense DNA, Small Interfering RNA (siRNA), MicroRNA (miRNA)
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of rintatolimod in triple-negative breast cancer (TNBC), sponsored by Roswell Park Comprehensive Cancer Center. Primary endpoint: Increase of CD8+ infiltration into tumor microenvironment. Started Jan 2019; status: completed.
02
Drugs
rintatolimod
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT03599453.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03599453.